Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
September 25, 2023 01:17 ET
|
Novartis Pharma AG
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced...
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
September 22, 2023 09:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
September 21, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
September 19, 2023 07:00 ET
|
Revolution Medicines, Inc.
KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers ...
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
September 18, 2023 01:15 ET
|
Novartis Pharma AG
Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half...
Cancer Immunotherapy Market Size to Reach USD 339.6 Billion by 2032 | CAGR: 14.5% | DataHorizzon Research
September 14, 2023 08:20 ET
|
DataHorizzon Research
Fort Collins, Colorado, Sept. 14, 2023 (GLOBE NEWSWIRE) -- DataHorizzon Research Published a report titled, "Cancer Immunotherapy Market Size, Growth, Share, Statistics Report, By Type (Monoclonal...
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 14, 2023 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the...
Association Sheds Light on Latest Advances of AHCC During Sexual Health Month
September 13, 2023 08:30 ET
|
AHCC Association
NEW YORK, Sept. 13, 2023 (GLOBE NEWSWIRE) -- With Sexual Health Month in full swing this September, the AHCC Association is urging individuals to enhance their understanding of sexual health,...
CARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific Officer
September 12, 2023 09:05 ET
|
CARGO Therapeutics, Inc.
– Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage development – SAN MATEO, Calif., Sept. 12, 2023 (GLOBE...
First Light Acquisition Group Announces NYSE Approval for Listing of Business Combination with Calidi Biotherapeutics and Additional New Capital Commitments
September 11, 2023 16:05 ET
|
First Light Acquisition Group
Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023 Gross proceeds made available to Calidi Biotherapeutics from transaction will total...